NICEVIVA
MONOGRAPH SPEC LATEST 2026

Beta-Glucan (1,3/1,6)

IMMUNE · Evidence Monograph

Beta-Glucan (1,3/1,6) is an evidence-graded immune monograph evaluated across 30 peer-reviewed PubMed studies (6 meta-analyses, 3 systematic reviews, and 8 randomized controlled trials, encompassing n = 11,862 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 30 Studies
Meta-Analyses · Reviews 6 Meta · 3 Systematic Reviews
Randomized Trials (RCT) 8 RCTs (6 Double-Blind)
Cumulative Participants n = 11,862
Reported Trial Dosages 3 g · 5 g/day · 100g
Trial Duration Range 6 weeks · 4 weeks · 8 weeks
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 30 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (3 g · 5 g/day · 100g) over a structured 6 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
With Breakfast or Lunch
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
cancer (PubMed clinical endpoint)
blood pressure (PubMed clinical endpoint)
inflammation (PubMed clinical endpoint)
gut (PubMed clinical endpoint)
weight (PubMed clinical endpoint)
01

What Is Beta-Glucan (1,3/1,6) & Why Does Form Matter?

Beta-Glucan (1,3/1,6) is classified under IMMUNE and has been investigated across 30 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (3 g, 5 g/day, 100g).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Beta-Glucan (1,3/1,6) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (8 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Beta-Glucan (1,3/1,6) acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Beta-Glucan (1,3/1,6) an overall evidence rating of GRADE High (4.0 / 4.0) based on 30 PubMed studies: 6 meta-analyses, 3 systematic reviews, and 8 randomized controlled trials (6 double-blind, n = 11,862 total participants).

Representative peer-reviewed findings include: • PMID:41558159 (2026) — "Review: A systematic review on the use and effects of postbiotics on the general health, gut health, and performance of sows and piglets." (In weaned pigs, postbiotic supplementation reduced pro-inflammatory cytokines (Tumour Necrosis Factor-α, Interleukin 1) • PMID:41362998 (2026) — "Cereal beta-glucan and cardiovascular disease risk reduction in overweight and obese populations: a systematic review and meta-analysis of lipid, blood pressure, and anthropometric parameters." (In conclusion, CBG reduces TC and LDL-C, and oat beta-glucan may modestly lower SBP in overweight and obese populations.) • PMID:40516031 (2026) — "Impact of non-digestible carbohydrates and prebiotics on immunity, infections, inflammation and vaccine responses: a systematic review of evidence in healthy humans and a discussion of mechanistic proposals." (Yeast β-glucan and GOS supplementation resulted in improvements in NK cell activity.)

Quantitative Clinical Effect-Size Distribution (Forest Plot)

Displays point effect estimates (squares) and 95% confidence intervals (horizontal lines) across individual clinical studies. Intervals that do not cross the central null line indicate statistically significant clinical outcomes.

Study (PMID · Year)MD Effect Size & 95% CI DistributionEstimate (95% CI)PMID 38441173-0.24 (-0.33–-0.15)PMID 36435335-2.82 (-4.72–-0.93)-5.4Null (0)0.71Metric: MD
05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 3 g · 5 g/day · 100g · 500 mg over 6 weeks · 4 weeks · 8 weeks · 30 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Beta-Glucan (1,3/1,6), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (3 g · 5 g/day · 100g) and re-evaluate efficacy after 6 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (30 Studies) · 17 Quantitative Analyses

01
SYSTEMATIC REVIEW Animal (2026) PMID: 41558159 ↗
Review: A systematic review on the use and effects of postbiotics on the general health, gut health, and performance of sows and piglets.
Clinical Trial Synthesis 2026 Systematic Review published in Animal. Key conclusion: In weaned pigs, postbiotic supplementation reduced pro-inflammatory cytokines (Tumour Necrosis Factor-α, Interleukin 1
View Original PubMed Abstract ↓

Growing concerns over antibiotic resistance have led to restrictions on antimicrobial use in various regions, including the European Union, prompting the search for alternative strategies to promote gut health. Of these, postbiotics have emerged as a promising strategy due to their potential immunomodulatory, anti-inflammatory, and gut barrier-enhancing properties. Despite extensive research regarding human health, the application of postbiotics in swine nutrition remains unexplored, with limited and inconclusive findings. The definition of postbiotics has evolved, leading to inconsistencies in the literature regarding their classification and functional properties. This review aimed to clarify the concept, the definition, and classification, and evaluate the types and effects of postbiotic supplementation on the health and performance of pigs. A literature search was conducted using PubMed, Google Scholar, Web of Science, and Scopus, employing search terms mainly related to "postbiotic preparation" (i.e., cell wall fragments, exopolysaccharides, etc.) and "pig category" (gestating and lactating sows, suckling and post-weaning pigs). The search yielded 2 151 articles (published between 1982 and 2025), and 33 fulfilled the eligibility criteria (studies on swine and studies in which the postbiotic respected the latest definition of the International Scientific Association for Probiotics and Prebiotics). The findings indicate that postbiotics derived from Saccharomyces cerevisiae and Lactobacillus species are the most extensively investigated. Based on the explored studies, the mechanisms of action of the various postbiotics appear to be closely linked to their specific bioactive components and, consequently, to the originating microbial strains. Postbiotics derived from both Saccharomyces cerevisiae and Lactobacillus demonstrated beneficial effects on gut health pillars in both sows and piglets. Sows' supplementation enhanced immunoglobulin concentrations in blood (31%) and milk (58%) while reducing oxidative stress markers (malondialdehyde, 34%). In weaned pigs, postbiotic supplementation reduced pro-inflammatory cytokines (Tumour Necrosis Factor-α, Interleukin 1

02
META-ANALYSIS Food & function (2026) PMID: 41362998 ↗
Cereal beta-glucan and cardiovascular disease risk reduction in overweight and obese populations: a systematic review and meta-analysis of lipid, blood pressure, and anthropometric parameters.
Clinical Trial Synthesis 2026 Meta-Analysis published in Food & function involving n = 3,854 participants; statistical significance reported at p = 0.001. Key conclusion: In conclusion, CBG reduces TC and LDL-C, and oat beta-glucan may modestly lower SBP in overweight and obese populations.
View Original PubMed Abstract ↓

Obesity-related dyslipidemia and hypertension are the key drivers of global cardiovascular disease (CVD) mortality. Although the lipid-lowering capacity of beta-glucan has been demonstrated in the general population, evidence regarding its effects on dyslipidemia and hypertension in overweight and obese populations remains limited. As of April 23, 2025, we searched nine databases. Two reviewers independently conducted study screening, data extraction, and bias assessment. We assessed the effects of cereal beta-glucan (CBG) on lipids, blood pressure, and anthropometric parameters in individuals with a body mass index (BMI) ≥25 kg m-2. This article included 49 eligible studies involving 3854 subjects. Pooled analyses showed that CBG significantly reduced total cholesterol [TC, -0.24 mmol L-1 (-0.31, -0.17), P < 0.001] and low-density lipoprotein cholesterol [LDL-C, -0.19 mmol L-1 (-0.25, -0.13), P < 0.001], particularly with doses ≥3 g day-1 and durations ≥6 weeks. Oat beta-glucan also lowered the systolic blood pressure [SBP, -1.38 mmHg (-2.66, -0.09), P = 0.036]. No effects were observed for triglycerides, high-density lipoprotein cholesterol, diastolic blood pressure, or body weight. BMI results were conflicting owing to publication bias. In conclusion, CBG reduces TC and LDL-C, and oat beta-glucan may modestly lower SBP in overweight and obese populations. These results support evidence-based recommendations for integrating CBG into CVD prevention strategies.

03
SYSTEMATIC REVIEW Critical reviews in food science and nutrition (2026) PMID: 40516031 ↗
Impact of non-digestible carbohydrates and prebiotics on immunity, infections, inflammation and vaccine responses: a systematic review of evidence in healthy humans and a discussion of mechanistic proposals.
Clinical Trial Synthesis 2026 Systematic Review published in Critical reviews in food science and nutrition. Key conclusion: Yeast β-glucan and GOS supplementation resulted in improvements in NK cell activity.
View Original PubMed Abstract ↓

Prebiotics, particularly non-digestible carbohydrates (NDCs), are increasingly recognized for their role in modulating immune responses in the gut, lungs, and urinary tract. This review systematically evaluates evidence from human studies on the effects of NDCs and prebiotics on immune markers, infection risk and severity, inflammation, and vaccine responses. Prebiotics such as inulin, galactooligosaccharides (GOS), and fructooligosaccharides (FOS) positively influence gut microbiota by promoting beneficial species like Bifidobacteria. They also enhance the production of short-chain fatty acids (SCFAs) like butyrate, which interact with immune cells via G-protein-coupled receptors, inducing anti-inflammatory effects. In addition to microbiota-mediated mechanisms, NDCs and prebiotics may directly affect immune and epithelial cells by interacting with pattern recognition receptors (PRRs), enhancing gut barrier function, and modulating immunity. A systematic review of human studies showed that prebiotics, including GOS, FOS, and 2'-fucosyllactose (2FL), reduced infections and increased IgA in healthy infants, while yeast β-glucan reduced respiratory infection symptoms in healthy adults. Yeast β-glucan and GOS supplementation resulted in improvements in NK cell activity. Some effects on vaccine efficacy were noted in young adults, but the overall impact of NDCs and prebiotics on vaccination and systemic inflammation was inconsistent. Further research is needed to clarify the mechanisms involved and to optimize health applications.

04
SYSTEMATIC REVIEW Nutrients (2025) PMID: 40290044 ↗
Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review.
Clinical Trial Synthesis 2025 Systematic Review published in Nutrients. Key conclusion: Conclusions: These findings highlight the potential of specific dietary supplements to improve various aspects of breast cancer care.
View Original PubMed Abstract ↓

Background: This systematic review aimed to evaluate the efficacy and safety of dietary supplements in breast cancer patients, focusing on their impact on clinical outcomes, treatment-related side effects, and therapy adherence. Methods: Only RCTs investigating the effects of various orally administered supplements in adult breast cancer patients were included. Well-defined substances like vitamins, minerals, antioxidants, and specific herbal extracts were explored. The review excluded studies solely based on dietary interventions or non-supplemental approaches. The primary outcome assessed was quality of life. Secondary outcomes included disease-free survival, overall survival, tumor response, and biomarkers indicative of disease progression. Results: A total of 45 randomized controlled trials (RCTs) were included in this systematic review. Overall, supplementation was not associated with serious adverse events in the included trials. Vitamin D supplementation showed promise in some studies, with potential immunomodulatory and antioxidant effects, particularly when combined with other interventions. Omega-3 fatty acids and beta-glucan demonstrated potential in alleviating certain symptoms and improving quality of life. Studies on amino acids like acetyl-L-carnitine and L-arginine also yielded mixed results. Beta-glucan exhibited potential for immune-enhancing effects, while melatonin and creatine showed limited or no benefit for fatigue or muscle strength. Herbal extracts, including silymarin, curcumin, and EGCG, had varied effects. Curcumin studies presented mixed results. Silymarin showed potential for hepatoprotective effects. Conclusions: These findings highlight the potential of specific dietary supplements to improve various aspects of breast cancer care. However, the evidence is mixed across supplement types, and further research is needed to determine the most effective and safe approaches.

05
META-ANALYSIS Food & function (2024) PMID: 38441173 ↗
Efficacy of oats in dyslipidemia: a systematic review and meta-analysis.
Clinical Trial Synthesis 2024 Meta-Analysis published in Food & function involving n = 1,731 participants (MD -0.24). Key conclusion: Conclusions: Oat-based products may reduce TC and LDL-C, but have little effect on TG, HDL-C, and major cardiovascular events in patients with dyslipidemia.
View Original PubMed Abstract ↓

Background: In recent years, oats' effect on lowering serum cholesterol has been recognized. However, no systematic reviews summarized the effect of daily consumption of oat-based products on serum lipids in patients with dyslipidemia. Methods: We searched eight databases and two clinical trial registries from inception to July 31, 2023. We included randomized controlled trials (RCTs) evaluating the efficacy of oat-based products (≥4 weeks) on lipid levels or cardiovascular events in patients with dyslipidemia. Two authors independently screened articles, extracted data and assessed the risk of bias of included studies with Cochrane risk-of-bias tool 2.0. We used STATA 17.0 to conduct meta-analysis and Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. Results: We finally included 17 eligible trials with 1731 subjects. The oat intervention varied from oat β-glucan-based products to oat bran-based products and wholegrain oat. Overall, the risk of bias of included trials was high or some concerns were noted because of the inadequate randomization, allocation concealment, and inappropriate data analysis method. Compared to the placebo or usual diet, one study indicated that oat-based products have no significant difference in major cardiovascular events. Pooled estimates showed that oat-based products may result in a large reduction in LDL-C (WMD, -0.24 mmol L-1; 95% CI: -0.33, -0.15) (moderate certainty) and TC (WMD, -0.32 mmol L-1; 95% CI: -0.48, -0.17) (moderate certainty). Compared to other diets (mainly other cereals), oat-based products probably reduce the level of LDL-C (WMD, -0.17 mmol L-1; 95% CI: -0.25, -0.08) (moderate certainty) and TC (WMD, -0.21 mmol L-1; 95% CI: -0.30, -0.12) (moderate certainty). Both groups showed that oat-based products had little effect on HDL-C and TG (moderate certainty). Oat-related adverse events were mostly gastrointestinal such as diarrhea, nausea, and flatulence being the most prevalent. Conclusions: Oat-based products may reduce TC and LDL-C, but have little effect on TG, HDL-C, and major cardiovascular events in patients with dyslipidemia.

06
META-ANALYSIS Medical mycology (2023) PMID: 37381179 ↗
Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis.
Clinical Trial Synthesis 2023 Meta-Analysis published in Medical mycology. Key conclusion: In conclusion, BDG testing may be useful in patients with suspected IF or IS.
View Original PubMed Abstract ↓

The (1→3)-β-D-glucan (BDG) is a component of the fungal cell wall that can be detected in serum and used as an adjunctive tool for the diagnosis of invasive mold infections (IMI) in patients with hematologic cancer or other immunosuppressive conditions. However, its use is limited by modest sensitivity/specificity, inability to differentiate between fungal pathogens, and lack of detection of mucormycosis. Data about BDG performance for other relevant IMI, such as invasive fusariosis (IF) and invasive scedosporiosis/lomentosporiosis (IS) are scarce. The objective of this study was to assess the sensitivity of BDG for the diagnosis of IF and IS through systematic literature review and meta-analysis. Immunosuppressed patients diagnosed with proven or probable IF and IS, with interpretable BDG data were eligible. A total of 73 IF and 27 IS cases were included. The sensitivity of BDG for IF and IS diagnosis was 76.7% and 81.5%, respectively. In comparison, the sensitivity of serum galactomannan for IF was 27%. Importantly, BDG positivity preceded the diagnosis by conventional methods (culture or histopathology) in 73% and 94% of IF and IS cases, respectively. Specificity was not assessed because of lacking data. In conclusion, BDG testing may be useful in patients with suspected IF or IS. Combining BDG and galactomannan testing may also help differentiating between the different types of IMI. Plain Language Summary: IF and IS are severe fungal infections for which diagnosis is often delayed. This meta-analysis shows that beta-glucan testing in serum had a sensitivity of about 80% for IF/IS and could detect the disease earlier compared to conventional diagnostic tests. © The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

07
CLINICAL STUDY Current opinion in allergy and clinical immunology (2023) PMID: 36821481 ↗
Wood dust and asthma.
Clinical Trial Synthesis 2023 Meta-Analysis published in Current opinion in allergy and clinical immunology. Key conclusion: There is a need for improved health-based international exposure standards and effective workplace control measures to reduce exposures to wood dust particulate (hard and soft woods), endotoxin and β-glucan, to reduce the risks of asthma in wood workers.
View Original PubMed Abstract ↓

PURPOSE OF THE REVIEW: Review recent developments on asthma associated with wood dust, given the increasing scale of wood handling and processing activities globally. RECENT FINDINGS: Work in wood industries is associated with a significantly increased risk of respiratory symptoms, rhinitis and asthma. This can be attributed to traditional processing techniques and newer technologies producing complex bioaerosol exposures, which may include chemicals. Meta-analysis studies indicate strong evidence for wood dusts as occupational sensitizers for asthma, but the underlying mechanisms remain poorly understood. The global prevalence of asthma in wood workers ranges between 6-18% and for rhinitis 16-33%. Exposure estimates show wide variation. Risk factors include atopy and exposure to certain wood species, elevated current and cumulative particulate exposures. SUMMARY: Future studies should focus on better characterization of wood dust allergens and other bioaerosol components, specific immunoglobulin E responses to different wood species, pathophysiological mechanisms underlying asthma, and modelling dose-response relationships using refined exposure metrics for dust particulate and other bioaerosol components. There is a need for improved health-based international exposure standards and effective workplace control measures to reduce exposures to wood dust particulate (hard and soft woods), endotoxin and β-glucan, to reduce the risks of asthma in wood workers.

08
META-ANALYSIS The American journal of clinical nutrition (2023) PMID: 36811560 ↗
Galactomannans are the most effective soluble dietary fibers in type 2 diabetes: a systematic review and network meta-analysis.
Clinical Trial Synthesis 2023 Meta-Analysis published in The American journal of clinical nutrition involving n = 2,685 participants. Key conclusion: CONCLUSIONS: Galactomannans were the most effective dietary fiber for reducing the levels of HbA1c, fasting blood glucose, triglycerides, and LDL cholesterol in patients with type 2 diabetes.
View Original PubMed Abstract ↓

BACKGROUND: Soluble dietary fibers are known to reduce the levels of blood glucose and lipids in patients with type 2 diabetes mellitus (type 2 diabetes). Although several different dietary fiber supplements are utilized, to our knowledge, no previous study has ranked their efficacy yet. OBJECTIVES: We performed this systematic review and network meta-analysis to rank the effects of different types of soluble dietary fibers. METHODS: We performed our last systematic search on November 20, 2022. Eligible randomized controlled trials (RCTs) included adult patients with type 2 diabetes and compared the intake of soluble dietary fibers with that of another type of dietary fiber or no fiber. The outcomes were related to glycemic and lipid levels. The Bayesian method was used to perform a network meta-analysis and calculate the surface under the cumulative ranking (SUCRA) curve values to rank the interventions. The Grading of Recommendations Assessment, Development, and Evaluation system was applied to evaluate the overall quality of the evidence. RESULTS: We identified 46 RCTs, including data from 2685 patients who received 16 types of dietary fibers as intervention. Galactomannans had the highest effect on reducing the levels of HbA1c (SUCRA: 92.33%) and fasting blood glucose (SUCRA: 85.92%). With regard to fasting insulin level, HOMA-IR, β-glucans (SUCRA: 73.45%), and psyllium (SUCRA: 96.67%) were the most effective interventions. Galactomannans were ranked first in reducing the levels of triglycerides (SUCRA: 82.77%) and LDL cholesterol (SUCRA: 86.56%). With regard to cholesterol and HDL cholesterol levels, xylo-oligosaccharides (SUCRA: 84.59%) and gum arabic (SUCRA: 89.06%) were the most effective fibers. Most comparisons had a low or moderate certainty of evidence. CONCLUSIONS: Galactomannans were the most effective dietary fiber for reducing the levels of HbA1c, fasting blood glucose, triglycerides, and LDL cholesterol in patients with type 2 diabetes. This study was registered at PROSPERO as ID CRD42021282984.

09
META-ANALYSIS Clinical nutrition ESPEN (2023) PMID: 36657917 ↗
The separate effects of whole oats and isolated beta-glucan on lipid profile: A systematic review and meta-analysis of randomized controlled trials.
Clinical Trial Synthesis 2023 Meta-Analysis published in Clinical nutrition ESPEN involving n = 1,494 participants; statistical significance reported at p = 0.00001. Key conclusion: CONCLUSION: Overall, this review showed that both oat and isolated β-glucan interventions improved lipid profiles.
View Original PubMed Abstract ↓

BACKGROUND & AIMS: It is well known that dietary fiber positively impacts the microbiome and health as a whole. However, the health effects of β-glucan, a dietary fiber extracted from oats, have been questioned when administered alone or incorporated into other foods. The purpose of this systematic review and meta-analysis was to evaluate the impact of oats or β-glucan supplements on the lipid profile. METHODS: Randomized controlled trials with parallel-arm or crossover blinded interventions at least two weeks in duration, for hyperlipidemic or non-hyperlipidemic men and women ≥18 years of age were selected. Only single (participants blinded) or double-blinded studies that compared oat or isolated β-glucan with a placebo/control group were considered for this review. The databases EMBASE, PubMed, Web of science and CINHAL were searched, from the earliest indexed year available online to the end of January 2022. Random-effects models were used to combine the estimated effects extracted from individual studies, and data were summarized as standardized mean difference (SMD) and 95% confidence interval (95%CI). RESULTS: A total of 811 articles were screened for eligibility, and relevant data were extracted from 28 studies, totaling 1494 subjects. Oat interventions TC (-0.61, 95%CI: -0.84;-0.39, p < 0.00001, and -0.70, 95%CI: -1.07;-0.34, p = 0.0002, respectively) and LDL (-0.51, 95%CI: -0.71;-0.31, p < 0.00001, and -0.38, 95%CI: -0.60;-0.15, p = 0.001, respectively). Moreover, isolated β-glucan interventions from parallel-arm studies decreased TC (-0.73, 95%CI: -1.01;-0.45, p < 0.00001), LDL (-0.58, 95%CI: -0.85;-0.32, p < 0.0001) and triglycerides (-0.30, 95%CI: -0.49;-0.12, p = 0.001). HDL was not altered by either oat or isolated β-glucan (p > 0.05). CONCLUSION: Overall, this review showed that both oat and isolated β-glucan interventions improved lipid profiles. Furthermore, the ingestion of oats or isolated β-glucan supplements are effective tools to combat dyslipidemia and should be considered in cardiovascular disease prevention.

10
META-ANALYSIS Journal of the Academy of Nutrition and Dietetics (2023) PMID: 36435335 ↗
Effect of Oat Consumption on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Clinical Trial Synthesis 2023 Meta-Analysis published in Journal of the Academy of Nutrition and Dietetics involving n = 1,569 participants; statistical significance reported at p = 0.004 (MD -2.82). Key conclusion: CONCLUSIONS: Oat consumption is effective in reducing SBP levels, particularly in individuals whose baseline BP is in the hypertensive range or when compared with control group participants consuming refined grains at matched total energy intake.
View Original PubMed Abstract ↓

BACKGROUND: Current clinical trials have had controversial results regarding the effects of oat consumption on blood pressure (BP) in adults. OBJECTIVE: The meta-analysis was conducted to systematically evaluate the effects of oat consumption on BP in adults. METHODS: Electronic databases including PubMed, Web of Science, Scopus, Cochrane Library, and Embase were searched until December 13, 2021 for eligible randomized controlled trials (RCTs). RCTs published in English and that explored the effects of oat consumption on BP in adults under matched total energy intake were included. Meta-analysis using a random-effects model was performed. The pooled effect size was expressed as mean difference and 95% CI. I2 statistics were used to quantify heterogeneity. The risk of bias was assessed using the Cochrane Risk-of-Bias Tool, version 2. RESULTS: Twenty-one RCTs involving 1,569 participants were included. The pooled results indicated that consuming oats reduced systolic blood pressure (SBP) significantly (mean difference = -2.82 mm Hg; 95% CI -4.72 to -0.93 mm Hg; P = .004). Subgroup analyses indicated that oat consumption reduced SBP significantly in hypertensive participants, or when compared with control group participants who consumed refined grains. No significant reduction in diastolic blood pressure (DBP) was observed after oat consumption (mean difference = -1.16 mm Hg; 95% CI -2.37 to 0.04 mm Hg; P = .060). However, the sensitivity analysis of DBP, removal of individual studies, or "leave one out meta-analysis," showed a significant reduction in DBP, suggesting that the pooled result in the main analysis was not robust. Subgroup analyses showed that oat consumption did significantly reduce DBP in participants with baseline BP in the prehypertensive range. Both SBP and DBP were significantly reduced when the dosage of oat consumption was ≥5 g/day β-glucan, or the oat consumption duration was ≥8 weeks. CONCLUSIONS: Oat consumption is effective in reducing SBP levels, particularly in individuals whose baseline BP is in the hypertensive range or when compared with control group participants consuming refined grains at matched total energy intake.

RELATED MONOGRAPHS

Related Monographs in This Category